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An isolated pe~fused rat kidney model was used to probe the renal disposition of quinapril and 
quinaprilat after separate administration of each drug species. Control studies were performed 
with drug-free pelfusate (n = 8) and perfusate containing quinapril (n = 9) or quinaprilat (n = 
7) at initial drug concentrations of 1000 ng/ml (including corresponding tracer levels of tritiated 
drug). Physiologic parameters were within the normal range of values for this technique and were 
stable for the duration of each experiment. Quinapril and quinaprilat concentrations were deter- 
mined in pelfusate, urine, and peJfusate ultrafiltrate using a specific and sensitive reversed-phase 
HPLC procedure with radiochemical detection, coupled to liquid scintillation spectrometry. Perfus- 
ate protein binding was determined using an ultrafiltration method at 37~ Tile total renal 
clearance of  quinapri/ ( CLr) was calculated as Dose/AUC(0-oo), and is represented by the sum 
of its urinas T and metabolic clearances. The urinal T clearances (CLe) of quinapril and quinaprilat 
were calculated as urina~ T excretion rate divided by midpoint pelfusate concentration for each 
respective species. Of the total renal clearance for quinapril (CLr=4.49 ml/min), less titan 0.1% 
was cleared as unchanged drug (CLe=O.O04 ml/min); over 99% of the drug was cleared as 
quinaprilat formed in the kidney. Tire clearance ratio of quinapril /CR = CLr/(fu - GFR)] was 
41.0, a value representing extensive tubular" secretion into the renal cells. Following quinaprilat 
administration, the clearance ratio of metabolite /CR  = CLe/(fu 9 GFR)] was 3.85, indicating a 
net secretion process for renal elimination. 
KEY WORDS: quinapril; quinaprilat; isolated perfused rat kidney; renal disposition; 
clearance. 
INTRODUCTION 
Angiotensin converting enzyme (ACE) inhibitors are a relatively new 
class of cardiovascular drugs that are gaining wider acceptance as a first- 
line therapy for hypertension and congestive heart failure (1,2). These drugs 
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inhibit the systemic conversion of angiotensin I to the potent vasoconstrictor, 
angiotensin II, thereby resulting in a lower blood pressure in healthy or 
hypertensive patients and a higher cardiac output in patients with heart 
failure (3-6). As antihypertensive agents, ACE inhibitors have also been 
shown to have significant effects on the kidney, including increases in glo- 
merular filtration rate, renal blood flow, and natriuresis (7). However, the 
effects of ACE inhibitors on renal hemodynamics may vary widely, depend- 
ing on the preexisting physiological and pathological state of the kidneys. 
Although the acute effects of ACE inhibitors may be directly related to 
reduced levels of angiotensin II in the plasma, inhibition of tissue ACE may 
be more important in determining the long-term response to these agents 
(5,8). This tenet is supported by several lines of experimental evidence. For 
example, it has been shown that ACE inhibitors are effective in "low renin" 
hypertensive states even when systemic renin-angiotensin has not been activ- 
ated. Second, studies in spontaneously hypertensive rats indicate that reduc- 
tions in blood pressure persisted for weeks after the ACE inhibitor was 
discontinued and plasma ACE activity returned to normal values; ACE in 
the vascular wall and kidney, however, remained inhibited. And finally, in 
addition to the pulmonary vasculature, ACE is present and may have sig- 
nificant pharmacologic activity in other tissues such as blood vessels, brain, 
heart, kidney, testis, and adrenals. In fact, since all components of the renin- 
angiotensin-aldosterone (RAA) system are also present within the kidney, 
it is possible that beneficial or undesired effects on renal function may be 
the result of both the systemic and local RAA systems. 
From a drug delivery standpoint, many of the ACE inhibitors have 
been formulated as prodrugs (e.g., alkyl esters) to improve bioavailability 
and drug performance. Once these compounds are absorbed, they are de- 
esterified primarily in the liver to their diacid active forms (4,9,10). In this 
context, enalapril (Vasotec | Merck) is hydrolyzed to enalaprilat and quin- 
april (Accupril | Parke-Davis) is hydrolyzed to quinaprilat (Fig. 1). 
Although human plasma esterases are incapable of hydrolyzing these ACE 
inhibitors (11,12), in vitro rat studies suggest that de-esterification may also 
occur in other extravascular tissues including the kidney (13,14). 
It has been shown that enalapril is extensively converted to its pharma- 
cologically active metabolite enalaprilat (90% conversion) in the isolated 
perfused rat kidney (15). In a subsequent study using a combined recirculat- 
ing liver-kidney perfusion model (16), total renal clearance accounted for 
30-40% of all elimination pathways. Thus, it appears that renal clearance 
can account for a substantial portion of the overall elimination of ACE 
inhibitor prodrugs, and that intrarenal metabolism is the predominant route 
of renal clearance in the rat. In addition, enalapril and enalaprilat have been 
reported to have different renal transport mechanisms; net reabsorption for 
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Fig. 1. Chemical structures of 3H-quinapril and 3H-quinaprilat. The asterisks denote the 
location of the two tritium atoms in each molecule. 
enalapril and net filtration for enalaprilat (15). Still, it should be appreciated 
that in the presence of renal drug metabolism, a significant portion of the 
drug may be unaccounted for in the urine. As a result, biotransformation 
of a drug within the kidney can complicate the interpretation of renal excre- 
tion data (17). 
Given the delicate relationship of renal drug transport and metabolism, 
and the apparent dependence of response on tissue dynamics, it is important 
to elucidate the renal handling of ACE inhibitors. With this in mind, the 
renal disposition of quinapril and quinaprilat were investigated, using iso- 
lated perfused rat kidneys, following the separate administration of each 
drug species. 
MATERIALS AND METHODS 
Perfusion Medium 
The kidney was perfused with a medium containing 6% bovine serum 
albumin (BSA, Fraction V; ICN Biomedicals, Irvine, CA) as the oncotic 
agent. The nutrients used were glucose (1 g/L) and a mixture of twenty 
essential L-amino acids (18) (Sigma Chemical Co., St. Louis, MO) with the 
following concentrations (mM): Leu (0.40), Phe (0.32), Met (0.33), Lys 
(1.00), Ile (0.31), Val (0.33), His (0.24), Thr (0.30), Trp (0.07), Aia (1.98), 
Gly (2.35), Arg (0.51), Pro (0.31), Tyr (0.20), Cys (0.50), Asp (0.20), Glu 
(0.50), Asn (0.20), Gln (2.00), and Ser (1.00). The BSA and nutrients were 
dissolved in a modified Krebs-Henseleit bicarbonate buffer (19) with the 
following component concentrations (mM): Na + (144), K + (5.04), Ca 2+ 
(1.28), Mg 2+ (1.19), CI- (126), HCO~- (24.8), SO 2- (1.19), H2PO~ (1.19). 
The perfusion medium was prepared in batch, frozen, and stored at -70~ 
A 200-ml aliquot of perfusion medium was thawed and filtered (42-ram 
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prefilter paired with a 47-mm, 0.45-pm membrane filter; Millipore Corpora- 
tion, Bedford, MA) at room temperature immediately before use. The per- 
fusion medium was aerated with humidified 02: CO2 (95 : 5) for at least 1 hr 
before rat kidney arterial cannulation and throughout the duration of the 
isolated perfused kidney (IPK) experiment. The total apparatus perfusate 
volume was 100 ml and perfusate pH was adjusted, if necessary, to 7.4 
throughout the experiment. The remaining perfusate was used for volumetric 
replacement of perfusate samples taken during the study, and for initial 
cannulation of the renal artery prior to perfusate recirculation. 
Animals 
Male Sprague-Dawley rats (328-464 g; Charles River Laboratories, 
Wilmington, MA) were used as kidney donors for all the IPK experiments. 
Animals were housed and cared for under the supervision of the University 
of Michigan's Unit for Laboratory Animal Medicine (ULAM). Animals 
were acclimated in their new housing for at least 3 days after acquisition 
and were allowed free access to food and water before experimentation. 
Surgical Procedure 
The experimental approach was adopted from those described by 
Nishiitsutsuji-Uwo et  al. (20) and Bowman (21) with minor modifications. 
Rats were weighed and anesthetized with sodium pentobarbital (64.8 pg/g 
body weight, intraperitoneal). After induction of deep anesthesia (approxi- 
mately 15 min), the rats were transferred to a surgical tray and secured in 
a supine position. The left superficial femoral vein was exposed and was 
used to administer a bolus of mannitol (180 rag; 10% normal saline solution) 
and heparin (200 U; 1000 U/ml solution). 
A midline incision was then made, the viscera gently positioned to one 
side, and the major abodminal blood vessels were isolated. The right ureter 
was catheterized with 10 cm of PE-10 polyethylene tubing (leading edge cut 
at a 45 ~ angle to facilitate insertion, 0.28 mm i.d., 0.61 mm o.d. ; Clay Adams, 
Parsippany, N J) and secured with three ligatures. Distal and proximal ligat- 
ures were placed around the superior mesenteric artery, and a single ligature 
was set around the right renal artery. The distal mesenteric ligature was tied 
and a serrefine (Diethrich, 2-inch with 8-mm serrated jaws, 50 g pressure; 
Biomedical Research Instruments, Inc., Rockville, MD) was placed on the 
mesenteric artery close to the aorta. A small cut was made in the mesenteric 
artery and a 19-gauge stainless stell cannula (hypodermic needle cut to 1.5- 
inch long, bent at a right angle 0.5 inch from the tip which was rounded; 
Pepper and Sons, New Hyde Park, NY) was inserted distally into the mesent- 
eric artery up to the depth of the serrefine. The serrefine was removed, and 
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the cannula was manipulated across the aorta and into the right renal artery. 
Perfusion flow was initiated as soon as the cannula entered the renal artery, 
thereby minimizing interruption of flow to the kidney. After the proximal 
mesenteric and renal artery ligatures were secured, the kidney was rapidly 
excised from the animal and carefully trimmed of adhering tissue. 
Approximately 20 ml of perfusate were allowed to pass through the 
kidney to remove any residual blood before recirculation was started, The 
kidney surface was also cleansed with normal saline during this pre- 
recirculation period. The kidney was transferred to the perfusion apparatus 
which was completely enclosed within a Plexiglas T M  chamber maintained at 
37~ Perfusion pressure at the tip of the renal cannula was kept at about 
80 mm Hg (corrected for intrinsic apparatus pressure) by monitoring the 
manometer and adjusting the flow-restriction valve accordingly. Surgery was 
normally completed within 10-15 min. 
Perfusion Apparatus 
A schematic of the recirculating IPK apparatus is illustrated in Fig. 2. 
Perfusion medium was pumped from the perfusate reservoir by a peristaltic 
roller pump (Model 502-S170; Watson-Marlow, Inc., Marblehead, MA), 
passed through a system of four parallel filters (22-mm prefilter paired with 
a 25-mm, 8-pm membrane filter; Millipore Corporation, Bedford, MA), 
and on to an oxygenator. The multibulb oxygenator assured complete spread 
of the perfusion medium over its surface. The 02:CO2 mixture, bubbled 
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Fig. 2. Illustration of the recirculating isolated perfused rat kidney 
apparatus. 
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through a gas-washing bottle containing water, entered at the bottom of 
the oxygenator (6 L/min) and the excess gas passed through an outlet 
at the top of the oxygenator. The perfusate then passed through the 
pump again and its flow was divided by a two-way tubing connector to a 
flowmeter (Type R-2-15-A with Size 2 Tantalum Float; Thomas Company, 
Philadelphia, PA) and through a flow-restriction valve (Whitey, Cleveland, 
OH) which emptied into the reservoir. This valve was adjusted so that 
different flow rates and associated pressures could be attained. The flow and 
pressure were monitored continuously, using the flowmeter and a manometer 
(sphygmomanometer, pocket aneroid type; Tycos Instruments, Inc., Arden, 
NC), and values were recorded every 10 min during each experiment coin- 
ciding with perfusate sampling. The manometer was protected from direct 
contact with the perfusate by an in-liner filter (Acrodisc | CR PTFE, 0.45- 
/~m, 25-mm diameter; Gelman Sciences, Ann Arbor, MI). 
A kidney tray, fashioned by tightly stretching a nylon mesh over a 7.5- 
cm diam sheet metal ring, prevented loose tissue from entering the reservoir. 
A horizontal limb, mounted 2.5 cm above the tray, supported the cannulated 
kidney. The tray was positioned in the top half of a glass funnel (13-cm 
height x 8.5-cm diam) designed to conduct perfusate back to the reservoir. 
The perfusate sampling port (flashback from a Venoset | Microdrip| 
Abbott Laboratories, North Chicago, IL) was located at the bottom of the 
oxygenator where excess perfusate could reenter the reservoir. Urine was 
collected via a ureter catheter placed through a side-arm of the glass funnel. 
Qulnapril and Quinaprilat 
3H-Quinapril and 3H-quinaprilat were obtained from Amersham 
Buchler GmbH & Co. KG, Braunschweig, Germany. Radiochemical purity 
of both compounds was determined to be >98% by HPLC. Specific activities 
were 8.80 and 9.10 Ci/mmol for 3H-quinapril and 3H-quinaprilat, respec- 
tively. Unlabeled quinapril (hydrochloride) and quinaprilat (monohydrate) 
were obtained from Parke-Davis, Ann Arbor, MI. Purity of both compounds 
was determined to be >99% by HPLC. For the IPK studies, 0.200 ml of 
3H-quinapril stock solution (47.9/lg/ml in acetonitrile:0.05M potassium 
phosphate) was combined with 0.904 ml of unlabeled quinapril (I0 mg dis- 
solved to 100 ml with water), evaporated under a gentle stream of nitrogen, 
and rapidly reconstituted with 1 ml of blank perfusate to give a total quin- 
april dose of 100/1 g. For IPK studies with quinaprilat, a 0.150 ml aliquot of 
3H-quinaprilat stock solution (43.4/,g/ml in acetonitrile:0.05M potassium 
phosphate) was combined with 0.935 ml of unlabeled quinaprilat (10 mg 
dissolved in 5 ml methanol and diluted to 100 ml with water), evaporated 
under a gentle stream of nitrogen, and rapidly reconstituted with 1 ml of 
blank perfusion medium to give a total quinaprilat dose of 100 pg. 
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Experimental Protocol 
Following a 15-min period for equilibration, 14C-inulin (0.150 ml of a 
16.7 pCi/ml solution, specific activity 2.5 pCi/mg; ICN Biomedicals Inc., 
lrvine, CA) and ACE inhibitor (3H-quinapril or 3H-quinaprilat) were intro- 
duced as a bolus to the recirculating perfusion medium. An additional 15 min 
were allowed for drug distribution and hemodynamic stability to occur. The 
remaining 90 min of perfusion time were divided into 10-min urine collection 
intervals for the evaluation of physiologic and urinary clearance parameters. 
Urine was collected into, and its volume measured with, a l-cc tuberculin 
syringe. Perfusate (1.5ml) was withdrawn with a 3-cc syringe (21-gauge 
needle) at the midpoint of each clearance interval. Additional urine (0- 
15min) and perfusate (10min) samples were collected during the 0- 
15 minute postbolus equilibration period. These additional samples were 
used for quinapril and quinaprilat pharmacokinetic calculations only, in 
which 0-t or 0-oo time data were required (e.g., Ae, A UC). Changes in 
perfusate composition due to the collection of urine and perfusate samples 
were minimized by isovolumetric replacement with modified Krebs- 
Henseleit buffer and blank perfusion medium (no inulin present), respec- 
tively. Perfusate and urine pH were determined immediately after collection 
(Model oTM-61, pHITM; Beckman Instruments, Inc., Irvine, CA). A schem- 
atic representation of the experimental time schedule is presented in Fig. 3. 
Nine experiments were conducted to define the disposition of quinapril 
and quinaprilat in the IPK after administration of quinapril, and seven 
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Fig. 3. Schematic representation of the experimental time schedule for IPK 
studies with quinapril and quinaprilat. 
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IPK after administration of quinaprilat. The initial perfusate concentrations 
of quinapril and quinaprilat were 1000 ng/ml following their respective 
doses. Eight control studies (no ACE inhibitor present) were also performed 
to establish baseline physiology and viability of the IPK model. 
Analytical 
14C-Inulin concentrations were determined in perfusate and urine 
samples by dual label spectrometry. Briefly, a 100-/Jl aliquot of perfusate 
or urine was combined with 15 ml of scintillation cocktail (Ready SafeTM; 
Beckman Instruments Inc., Fullerton, CA) in 20-ml glass scintillation vials. 
Samples were mixed thoroughly, allowed to settle in the dark for 24 hr, and 
each counted for 20 min or until a l%-2cr error was reached by liquid 
scintillation spectrometry (LS 7500; Beckman Instruments Inc., Arlington 
Heights, IL). Values of counts per minute (cpm) and quench were converted 
to disintegrations per minute (dpm) using an established 3H/14C dual-label 
quench curve. 
Perfusate and urine glucose concentrations were determined by a 
method employing an immobilized glucose oxidase membrane coupled to 
an electrochemical sensor (Model 27; Yellow Springs Instruments, Yellow 
Springs, OH). The procedure required a sample volume of 25 p l and concen- 
tration was reported by the instrument in units of mg/dl. The instrument 
was zeroed between each sample against a buffer background and calibrated 
frequently with a 100 mg/dl glucose reference solution. Replicate measure- 
ments (n = 16) of the glucose reference solution gave a mean bias within 
+2% and a coefficient of variation of less than 2%. 
Sodium concentrations were determined in perfusate and urine samples 
by flame photometry (Model 480; Ciba-Corning Diagnostics Corp., Med- 
field, MA). Approximately 75 lzl of sample was used by the instrument for 
each determination and concentration was reported by the instrument in 
units of mmol/L. The sample was combined with an internal standard solu- 
tion to compensate for fluctuations in the flame and diluted automatically 
with deionized water prior to excitation. Replicate measurements (n= 16) 
of the sodium reference solution gave a mean bias within +2% and a 
coefficient of variation of less than 2%. 
Quinapril and quinaprilat concentrations were determined in perfusate, 
urine, and perfusate ultrafiltrate using a specific and sensitive reversed-phase 
HPLC procedure with radiochemical detection, coupled to liquid scintilla- 
tion spectrometry (22). Briefly, cpm values were converted to dpm values 
using an established 3H/~4C dual-label quench curve. Liquid scintillation 
counting data (dpm) were multiplied by fractional chromatographic areas 
(drug 3H-peak area/total 3H-peak area) and total drug amounts were then 
calculated using the corresponding specific activities. 
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Protein Binding 
The binding of quinapril and quinaprilat to perfusate albumin was 
determined by ultrafiltration. Binding experiments were performed using a 
disposable micropartition device (Centrifree| Amicon Div., W. R. Grace 
& Co., Danvers, MA). The device employs an anisotropic, hydrophilic YMT 
membrane that excludes molecules larger than approximately 30 kdal. A 
0.6-ml aliquot of perfusate was introduced to the device, capped, equilibrated 
at 37~ for 15 min in a fixed 35 ~ angle rotor, and then centrifuged (IEH- 
HN II; Damon/IEC Division, Needham Heights, MA) at 1800 g for 20 min 
at 37~ When necessary, perfusate pH was adjusted to 7.4 by gassing the 
sample with CO2 or by vortexing the sample to remove excess CO2. Approxi- 
mately 350 pl of protein-free ultrafiltrate were harvested from each sample. 
Stability of Quinapril in Isolated Perfused Kidney 
The stability of quinapril was determined in recirculated perfusate and 
generated urine from IPK experiments. These experiments were similar to 
IPK studies described previously (but with no inulin or drug present), and 
were performed to determine if extracellular metabolism of quinapril occurs 
in the IPK model. Thus, isolated rat kidneys were perfused (n = 3) and the 
perfusate sampled at 40, 80, and 120 min and urine collected over intervals 
of 0-40, 40-80, and 80-120 rain. These samples were then used to incubate 
spiked quinapril at concentrations of 10 and 1000 ng/ml at 37~ The spiked 
samples were incubated for 40, 80, and 120 min, quenched with acetonitrile, 
and then assayed for quinapril and and quinaprilat by HPLC procedure 
described previously. 
Data Analysis 
The renal clearances of inulin, glucose, and sodium were determined 
by dividing the urinary excretion rate of each substance by its respective 
perfusate concentration at the midpoint time interval. The fractional urinary 
clearances of glucose (FEglucose) and sodium (FEsodium) were calculated 
as the renal clearance of each species divided by glomerular filtration rate 
(GFR). The renal clearance of inulin was taken to represent GFR. 
In IPK studies with quinapril, the total renal clearance of drug is repre- 
sented by the sum of its urinary and metabolic clearances (i.e., CLr= 





296 Kugler, Olson and Smith 
where A UC(O-oo) is the area under the perfusate drug concentration-time 
curve from time zero to infinity. A UC(O-oo) values were determined using 
the log-trapezoidal rule for experimental data, and extrapolated to infinity 
using Cplast/Az. The extrapolated area was about 2% of the total A UC for 
IPK studies with quinapril. The log-linear terminal half-life (Tj/2) of quin- 
april was calculated as ln(2)/Az; the rate constant (Zz) was estimated from 
the slope of a least-squares linear regression of the natural logarithm perfus- 
ate drug concentration-time profile during the terminal phase. The total 
renal clearance of quinapril was normalized for the fraction unbound (fu) 
and renal function (i.e., GFR) through calculation of its clearance ratio (CR; 
determined using the total renal clearance method). 
CLr 
CR = - -  (2) 
fu .  CFR 
The urinary clearance of quinapril was calculated for each urinary collection 
period as 
U . V  
CLe = - -  (3) 
Cpmid 
where U is the concentration of quinapril in urine, Cpmid is its midpoint 
perfusate concentration, and V is the urinary flow rate. And finally, the 
metabolic clearance of quinapril (CLm) was calculated as 
CLm = CLr-  CLe (4) 
In IPK studies with quinaprilat (after administration of quinapril or 
quinaprilat), the urinary clearance of quinaprilat (CLe) was calculated in 
an analogous manner to that of quinapril, using Eq. (3). The urinary clear- 
ance of quinaprilat was then normalized for the fraction unbound (fu) and 
renal function (i.e., GFR) through calculation of its clearance ratio (CR; 
determined using the urinary clearance method) 
CLe 
CR = - -  (5) 
fu .  GFI~ 
Due to quinaprilat's slow rate of decay from the perfusate, T1/2 and A UC(O- 
oo) estimates for quinaprilat were not reported. For the same reason, quin- 
aprilat's renal clearance is more accurately determined when dividing its 
urinary excretion rate by the corresponding midpoint perfusate 
concentration. 
For both quinapril and quinaprilat studies, the cumulative amount of 
drug excreted in the urine from Time 0 to 105 min [Ae(0-105)] was also 
determined, and is expressed as percentage of the administered dose. The 
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free fraction (fu) of drug in the perfusate, expressed as a percentage, was 
calculated as 
Perfusate Ultrafiltrate Drug Concentration 
fu(%) 100% (6) 
Perfusate Drug Concentration 
Data are reported as the mean +SD, unless otherwise indicated. To 
test for statistically significant parameter differences among groups, one-way 
analysis of variance (ANOVA) was performed. When the F ratio showed 
that there were significant differences among groups, the Student-Newman- 
Keuls method of multiple comparisons was used to determine which groups 
differ. All statistical tests employed an a = .05 significance level. Means that 
were not significantly different were reported with the same capital letter in 
tables. All statistical computations were done using SAS 5.18 software (SAS 
Institute; Cary, NC). 
RESULTS 
Physiologic Parameters 
Perfusion pressure, perfusate flow rate, GFR, FEglucose, FEsodium, 
urine flow rate, and urine pH were evaluated as indices of renal functionality 
in control, quinapril and quinaprilat IPK studies (Table I). Although renal 
function was similar between the drug and control groups, some minor 
differences did exist. GFR was 25% greater in quinapril vs. control, urine 
flow rate was 37-58% larger in drug vs. control, and urine pH was increased 
in quinapril vs. control studies. There were no significant differences in IPK 
function when comparing quinapril vs. quinaprilat administration with one 
exception; GFR differed by about 20% in these studies. Overall, physiologic 
parameters were within the normal range of values for this technique (23- 
28), and were stable for the duration of each experiment. 
Stability of Quinapril in Isolated Perfused Kidney 
In these preliminary experiments, quinapril degradation was not 
observed under any of the conditions studied. These results demonstrate 
that the kidney is not releasing enzymes that can de-esterify quinapril in 
the recirculating perfusate or generated urine over the course of the IPK 
experiments. Therefore, in the IPK model any esterolysis of quinapril can 
be attributed to cellular kidney metabolism. Similar results were also 
observed for enalapril in the isolated red blood cell-peffused rat kidney (15). 
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Drug Studies 
When quinapril was administered to the IPK, perfusate concentrations 
of parent drug declined raPidly with a T~/2 of 16.5 :t: 1.5 min (Fig. 4). Quin- 
aprilat was formed rapidly and extensively (from quinapril) within the kid- 
ney and tended to accumulate with time. When metabolite was administered, 
quinaprilat was eliminated slowly from the perfusate, and intrarenally 
formed and preformed quinaprilat levels appear indistinguishable _> 60 min 
postdose. Thus, once quinapril was largely removed from the perfusate, the 
kidney handled quinaprilat in a similar fashion regardless of its source. 
After quinapril administration (Table II), the clearance ratio of parent 
drug was 41.0 [using the total renal clearance method of Eq. (2)], indicating 
that quinapril undergoes an extensive tubular secretion into the renal epithel- 
ial cells. Of the total renal clearance (CLr = 4.49 ml/min), less than 0.1% of 
quinapril was cleared as unchanged drug (CLe =0.004 ml/min); over 99% 
of the drug was cleared as metabolite formed in the kidney (CLm = 4.48 ml/ 
min). Metabolic clearance reflects that of quinaprilat since no other metabo- 
lites were formed in the kidney. The fraction unbound was 13% for quinapril, 
and protein binding was linear over the drug concentrations studied. 
Following quinaprilat administration (Table II), the clearance ratio of 
metabolite was 3.85 [using the urinary clearance method of Eq. (5)], which 
indicates a net secretion process for its renal elimination. In addition, the 
clearance ratio of quinaprilat after quinapril administration was 4.73, a value 
that was variable as a function of time (Fig. 5). Nevertheless, the clearance 
-~ 1000 
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Fig. 4 Perfusate concentration-time curves for quinapril 
(Q) and quinaprilat (QAT :Q) after administration of quin- 
april (n = 9), and for quinaprilat (QAT :QAT) after admin- 
istration of quinaprilat (n= 7). Data are shown as mean 
d:SEM (error bars may be hidden by the symbol). 
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Fig. 5. Clearance rat io-t ime curves for quinaprilat (QAT :Q) 
after administration of  quinapril (n = 9), and for quinaprilat 
(QAT :QAT) after administration of quinaprilat (n = 7). Data 
are shown as mean :i:SEM (error bars may be hidden by the 
symbol). 
ratios of intrarenally formed and preformed quinaprilat are essentially the 
same by > 60 min postdose. This finding indicates that once quinapril has 
been effectively removed from the system, the renal clearance of quinaprilat 
is the same regardless of its origin. 
Although the fraction unbound for quinaprilat is statistically different 
following parent or metabolite dosing, this difference is small (about 10%), 
and does not appear to reflect a competitive interaction between drug species. 
Overall, the fraction unbound was 20-25% for quinaprilat, and binding was 
linear over the narrow range of metabolite concentrations observed. 
In contrast to quinapril excretion, about 25-35% of quinaprilat was 
recovered in the urine unchanged. It should be appreciated that after quin- 
aprilat dosing, the urinary clearance and total renal clearance of quinaprilat 
are equivalent since the preformed metabolite is eliminated by renal excretion 
only (i.e., no metabolism occurs). However, the urinary clearance of quin- 
aprilat (after quinapril dosing) reflects the contributions of quinaprilat's 
renal excretion from the recirculating perfusate and that which is formed 
from quinapril in the renal tubular cells. 
DISCUSSION 
In determining the net renal transport mechanism of a drug, it is implic- 
itly assumed that metabolism by the kidney does not occur. Under this 
assumption, the renal clearance of a compound is accounted for by the 
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individual contributions of glomerular filtration, secretion, and reabsorption 
processes. Intrarenal metabolism usually occurs within the tubular cells and, 
as a result, the amount of unchanged drug leaving the proximal tubular 
cell across the brush border membrane is considerably less than what was 
presented at the basolateral membrane. It is also possible that intrarenal 
metabolism may occur at sites distal to secretion as well as at luminal mem- 
brane surfaces. In each case, renal drug metabolism would substantially 
reduce the urinary recovery of intact drug, thereby, masking the contribution 
of secretory transport mechanisms. In this regard, the clearance ratio of 
enalapril (using the urinary clearance method) was reported as 0.55 in the 
recirculating, constant pressure IPK model (15), suggesting net reabsorption. 
However, this conclusion is tenuous since the method of analysis did not 
account for the fact that over 90% of enalapril's total renal clearance is 
metabolic (i.e., intrarenal formation of enalaprilat). As an alternative 
method of analysis (17), we calculated the clearance ratio of enalapril (using 
the total renal clearance method) as 7.8, a result indicative of significant 
renal tubular secretion. Therefore, it seems reasonable to speculate that, in 
fact, enalapril is highly secreted into the renal tubular cells of the kidney, 
but that this process is masked by its subsequent and substantial intrarenal 
metabolism. 
In the present IPK study, a negligible amount of quinapril (<0.1%) was 
excreted into the urine as unchanged drug, resulting in a urinary clearance of 
only 0.004 ml/min. Using the urinary clearance method, the clearance ratio 
of quinapril was calculated as 0.032. Based on this information alone, one 
would conclude that quinapril was transported by the kidney via a net 
reabsorption process. However, this would be an incorrect interpretation 
because over 99% of quinaprii's total renal clearance is reflected by intrarenal 
metabolism. In contrast, the clearance ratio of quinapril was calculated as 
41.0 (using the total renal clearance method), a value indicative of substan- 
tial tubular secretion. This conclusion is supported by preliminary experi- 
ments in the IPK (29) where the renal transport of quinapril was inhibited 
in a dose-dependent manner by organic anions (e.g., probenecid, p- 
aminohippurate) but not by organic cations (e.g., tetraethylammonium, qui- 
nine). Thus, the IPK studies with quinapril agree with our previous theoreti- 
cal analysis (17), suggesting that for drugs in which all of the elimination 
processes are renal (transport and metabolic), total renal clearance is a better 
predictor of secretory transport processes tllan is urinary drug clearance. The 
ability of renal metabolism to mask secretory transport was also reported by 
Acara et al. (30) in micropuncture studies with choline. In these studies, a 
net secretion of choline was not observed at low plasma concentrations 
(<325/zM) because of extensive metabolism to betaine by the proximal 
tubular cell. However, when the plasma concentrations were increased (325-  
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1000/~M), intracellular metabolism of choline was largely saturated, and 
secretion of choline became apparent. 
Despite a larger urinary clearance of generated quinaprilat as compared 
to the preformed metabolite, this difference was not significant once the 
clearance was normalized for GFR. Thus, the average clearance ratio of 
quinaprilat was approximately 4, indicating a net secretory mechanism for 
its overall renal transport. However, it should be appreciated that while 
the clearance of preformed metabolite (i.e., after dosing quinaprilat) was 
reasonably constant over the experimental time frame of IPK experiments, 
the clearance of generated metabolite (i.e., after dosing quinapril) was vari- 
able and time-dependent. This variability is predicted by Eq. (3) since the 
excreted metabolite has two sources, namely, that formed intrarenally from 
quinapril and that from prior reabsorption of quinaprilat into the recirculat- 
ing perfusate. In the early time periods, quinaprilat excretion is dominated 
by quinapril to quinaprilat conversion while the perfusate concentrations of 
quinaprilat are low. In the later time periods, quinaprilat excretion is domi- 
nated by urinary clearance of reabsorbed metabolites while the perfusate 
concentrations of quinaprilat have accumulated. Thus, the clearance ratio 
of quinaprilat after quinapril administration is initially large, followed by 
smaller values approaching an asymptote (see Fig. 5). Finally, the clearance 
ratios of intrarenally formed and preformed quinaprilat are essentially the 
same as the supply of quinapril in perfusate becomes exhausted. This finding 
is in close agreement with a study performed on enalapril and enalaprilat 
in the isolated red blood cell-perfused rat kidney (15). 
In rat IPK experiments, it was observed that quinapril was not metabol- 
ized to any other drug species other than quinaprilat, and that after quin- 
aprilat administration, no other metabolites were found. In this context, the 
metabolic profile of whole organ studies is consistent with results from in 
vitro (31) as well as in vivo (11) experiments in rats. A comparison of 
IPK studies with that of humans is more difficult since information on the 
intrarenal metabolism of ACE inhibitors is lacking. Notwithstanding this 
omission, it appears that both quinapril and quinaprilat are cleared by the 
human kidney through a net secretion process; in both instances, we estima- 
ted their urinary clearance ratios at > 10 (32). 
In conclusion, the disposition of quinapril and quinaprilat were evalua- 
ted in an isolated perfused rat kidney model. Quinapril was found to be 
substantially transported into renal proximal cells, as evidenced by a total 
renal clearance ratio of 41.0. Although the urinary clearance of quinapril 
was negligible, conversion to its active metabolite was rapid and essentially 
complete. Thus, it appears that quinapril is, for all practical purposes, exclus- 
ively metabolized by the kidney to quinaprilat, a process coupled to its active 
tubular secretion. After quinaprilat administration, the urinary clearance 
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ratio of  preformed metabolite was 3.85, a vale representing net tubular 
secretion. In addition, there were distinct differences in the temporal aspects 
of urinary drug clearance for generated vs. preformed metabolite. 
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